Posted on 9/24/20
Novavax Initiates Pivotal Study of COVID-19 Vaccine Candidate; Shares Up 5%
Novavax (NASDAQ:NVAX) launches a U.K.-based Phase 3 clinical trial evaluating COVID-19 vaccine candidate NVX-CoV2373 in up to 10K adult (ages 18-84) volunteers.Enrollment in the study, being . . .
Posted on 9/9/20
Gary Cohn And Sam Zell Among Those Launching Blank Check Companies
Cohn Robbins (NYSE:CRHC) last night raised $720M in an IPO. The SPAC is led by former Goldmanite and White House advisor Gary Cohn, and activist investor . . .
Posted on 8/19/20
J&J To Acquire Momenta Pharmaceuticals For $6.5B
Johnson & Johnson (NYSE:JNJ) has agreed to acquire Momenta Pharmaceuticals (NASDAQ:MNTA) for $52.50 per share in cash for a total of $6.5B.
Posted on 8/10/20
Novavax Secures $2B in Funding to Support COVID-19 Vaccine Development
Novavax (NASDAQ:NVAX) Q2 results:Revenue: $35.5M (+999%) from CEPI agreement.Net loss: ($17.5M); loss/share: ($0.30).Cash and equivalents at quarter-end: $424.4M (+438.6%).Secured $2B in funding to support development and . . .
Posted on 8/10/20
Bristol Myers' O+Y extends survival in rare type of thoracic cancer
Bristol Myers Squibb (NYSE:BMY) announces positive results from an open-label randomized Phase 3 clinical trial, CheckMate-743, comparing the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) (O+Y) . . .
Posted on 8/5/20
Novavax On Wild After-Hours Ride After Reporting COVID-19 Vaccine Data
At one point after hours, Novavax (NASDAQ:NVAX) was down ~30% after STAT News reported that eight participants in a Phase 1 clinical trial evaluating COVID-19 vaccine . . .
Posted on 8/4/20
Novavax Rebounds from Vaccine Data-Stoked Selloff on Clarified Safety Profile
Novavax (NASDAQ:NVAX) announces positive results from the first portion of its Phase 1/2 clinical trial evaluating its COVID-19 vaccine candidate, NVX-CoV2373, with and without the Matrix-M . . .
Posted on 7/24/20
Novavax Inks Manufacturing Deal For COVID-19 Vaccine
Novavax (NASDAQ:NVAX) enters into an agreement with CDMO FUJIFILM Diosynth Biotechnologies for the manufacture of bulk drug substance for NVX-CoV2373, its COVID-19 vaccine candidate.Production of the . . .
Posted on 7/23/20
United Therapeutics Sues Liquidia To Block Tyvaso Competitor
United Therapeutics (NASDAQ:UTHR) has filed litigation in a Delaware court against Liquidia Technologies (NASDAQ:LQDA) in response to the latter's U.S. marketing application seeking approval of LIQ861, . . .
Posted on 7/22/20
Altimmune Secures Supply Of COVID-19 Nasal Spray Vaccine
Altimmune (NASDAQ:ALT) inks an agreement with Rockville, MD-based CDMO Vigene Biosciences to manufacture its single-dose intranasal COVID-19 vaccine candidate AdCOVID.The company is in talks with additional . . .
Posted on 7/17/20
EU in Talks with Moderna and Others for COVID-19 Vaccine Supply
Reuters reports that the European Union (EU) is negotiating with Moderna (NASDAQ:MRNA), Sanofi (NASDAQ:SNY), Johnson & Johnson (NYSE:JNJ), BioNTech (NASDAQ:BNTX) and CureVac for advance purchases of . . .
Posted on 7/14/20
Boston Scientific to Sell Snake Venom Unit - Bloomberg
Boston Scientific (BSX +0.3%) is rumored to be putting its CroFab (Crotalidae Polyvalent Immune Fab [Ovine
Posted on 7/14/20
Thermo Fisher Under Mounting Pressure To Up Qiagen Bid - UFP
United First Partners chief Stephane Mardel says bullish preliminary results from life science toolmaker PerkinElmer (PKI +3.5%) is ratcheting up the pressure on Thermo Fisher Scientific . . .
Posted on 7/13/20
Thermo Fisher Bid For Qiagen Inadequate - Davidson Kempner
QIAGEN N.V. (QGEN +1.3%) is up modestly, albeit on below-average volume, on the heels of a letter to its board from institutional investor Davidson Kempner stating . . .
Posted on 7/10/20
Thermo Fisher Bid for Qiagen Inadequate - Davidson Kempner
QIAGEN N.V. (QGEN +1.3%) is up modestly, albeit on below-average volume, on the heels of a letter to its board from institutional investor Davidson Kempner stating . . .
Posted on 7/10/20
Marinus Pharma Inks $60M Stock Sales Deal With JMP
Marinus Pharmaceuticals (NASDAQ:MRNS) has filed a prospectus for a $250M mixed shelf offering.It has also entered into an agreement with JMP Securities for the at-the-market sale . . .
Posted on 7/10/20
NeuroMetrix Announces Expanded Distribution Of DPNCheck In China
NeuroMetrix (NURO +3.6%) announces that Omron Medical (Beijing) Ltd., its exclusive distributor of peripheral neuropathy test device DPNCheck in China, has inked a collaboration agreement with . . .
Posted on 7/8/20
Merck Inks New Deal with Zymeworks for up to Three Antibodies
Merck (NYSE:MRK) inks an agreement with longtime partner Zymeworks (NYSE:ZYME) for a global license to develop and commercialize up to three multispecific antibodies to Merck targets . . .
Posted on 6/26/20
Novartis To Pay ~$113M To Settle SEC Charges Of FCPA Violations
The Securities and Exchange Commission (SEC) announces that Novartis (NVS +0.7%) has agreed to pay $112.8M to settle claims that it violated the books and records . . .
Posted on 6/23/20
LaMaitre Vascular Acquires Artegraft For $90M
LaMaitre Vascular (NASDAQ:LMAT) has acquired North Brunswick, NJ-based Artegraft, a processor and seller of vascular grafts derived from bovine carotid arteries, for $90.0M
Posted on 6/8/20
Boston Scientific Nabs Medicare Reimbursement For Exalt Duodenoscope
The U.S. Centers for Medicare and Medicaid Services (CMS) has signed off on a transitional pass-through (TPT) payment category for single-use endoscopes, including Boston Scientific's (NYSE:BSX) . . .
Posted on 6/1/20
Pfizer Comes Up Empty In Ibrance Breast Cancer Study
Pfizer (NYSE:PFE) announces that, based on a futility analysis by the independent Data Monitoring Committee, a Phase 3 clinical trial, PALLAS, evaluating Ibrance (palbociclib) and adjuvant . . .
Posted on 6/1/20
Regeneron Completes Offering Of Sanofi-Held Stock
Regeneron Pharmaceuticals (NASDAQ:REGN) has finalized its secondary offering of ~13M common shares held by collaboration partner Sanofi (NASDAQ:SNY), including the full exercise of underwriters' option to . . .
Posted on 5/20/20
Boston Scientific Launches $1.5B Capital Raise
Boston Scientific (NYSE:BSX) commences concurrent $750M offerings of common stock and Series A mandatory convertible preferred stock.Prices, volumes and terms have yet to be announced.A portion . . .
Posted on 5/18/20
Novavax Inks $250M Stock Sales Deal
COVID-19 vaccine developer Novavax (NASDAQ:NVAX) enters into an agreement with B. Riley FBR for the at-the-market sale of up the $250M of its common stock.The agent . . .
Posted on 4/22/20
Boston Scientific Closes New $1.25B Loan
Aimed at boosting liquidity, Boston Scientific (NYSE:BSX) entered into a new one-year $1.25B term loan yesterday that it used to refinance borrowings under its credit revolver. . . .
Posted on 3/23/20
Bristol-Myers Squibb, Sanofi Strike Out In Bid To Stop Plavix Litigation
A Hawaii district court judge has dismissed a countersuit brought by Bristol-Myers Squibb (BMY +0.6%) and Sanofi (SNY -4.8%) in an attempt to stop the State . . .
Posted on 3/20/20
Teva To Donate 6M Doses Of Malaria Drug For Coronavirus Use
Teva Pharmaceutical Industries (NYSE:TEVA) announces the immediate donation of 6M doses of malaria med hydroxychloroquine sulfate tablets through wholesalers to U.S. hospitals to meet the demand . . .
Posted on 3/19/20
J&J Files U.S. Application For MS Med Ponesimod
Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical Companies has submitted a marketing application to the FDA for ponesimod for adults with relapsing multiple sclerosis (MS).MS is . . .
Posted on 3/19/20
Pfizer's Abrocitinib Successful In Dermatitis Study
A Phase 3 clinical trial, JADE COMPARE, evaluating Pfizer's (NYSE:PFE) JAK1 inhibitor abrocitinib in patients with moderate-to-severe atopic dermatitis met both co-primary endpoints of response rate . . .
Posted on 3/19/20
Pfizer Postpones Investor Event Due To Covid-19
Pfizer (NYSE:PFE) has postponed its March 31 Investor Day due to the threat of the coronavirus outbreak, adding that the timetable for rescheduling has not been . . .
Posted on 3/19/20
Seres Therapeutics Closes $25M Stock Sales Deal
Seres Therapeutics (NASDAQ:MCRB) inks an agreement with Cowen and Company for the at-the-market sale of up to $25M of its common stock. Cowen will earn a . . .
Posted on 3/12/20
Emergent BioSolutions To Develop Hyperimmune Candidates For COVID-19
Emergent BioSolutions (NYSE:EBS) initiates two new programs aimed at treating and preventing coronavirus infection based on its hyperimmune platforms.Human polyclonal hyperimmune with antibodies to SARS-CoV-2 (COVID-HIG) . . .
Posted on 12/20/19
Johnson & Johnson To Acquire Remainder Of Verb Surgical
On the heels of its successful collaboration with Alphabet's Verily Life Sciences, Johnson & Johnson (NYSE:JNJ) has agreed to acquire the remaining stake in robotics and . . .
Posted on 12/20/19
Johnson & Johnson To Acquire Remainder Of Verb Surgical
On the heels of its successful collaboration with Alphabet's Verily Life Sciences, Johnson & Johnson (NYSE:JNJ) has agreed to acquire the remaining stake in robotics and . . .
Posted on 12/18/19
FDA Advisory Committee Backs Merck's Keytruda for NMIBC
The FDA's Oncologic Drugs Advisory Committee voted 9-4 that the benefits outweigh the risks of Merck's (NYSE:MRK) Keytruda (pembrolizumab) for the treatment of bacillus Calmette-Guérin-unresponsive, high-risk, . . .
Posted on 12/18/19
FDA Advisory Committee Backs Merck's Keytruda for NMIBC
The FDA's Oncologic Drugs Advisory Committee voted 9-4 that the benefits outweigh the risks of Merck's (NYSE:MRK) Keytruda (pembrolizumab) for the treatment of bacillus Calmette-Guérin-unresponsive, high-risk, . . .
Posted on 11/20/19
Hologic To Sell Cynosure Aesthetics Unit For Net $138M
Hologic (NASDAQ:HOLX) has agreed to sell its Cynosure medical aesthetics business to an affiliate of funds managed by Clayton, Dubilier & Rice for $205M in cash, . . .
Posted on 7/12/19
FDA Accepts Neurocrine's opicapone Application for Parkinson's
The FDA accepts for review Neurocrine Biosciences' (NASDAQ:NBIX) marketing application seeking approval to use opicapone, a once-daily, oral catechol-O-methyltransferase (COMT) inhibitor, for the adjunctive treatment (to . . .
Posted on 7/2/19
ATyr Pharma (Nasdaq: LIFE) Reverse Splits Stock 1:14
Aimed at regaining compliance with Nasdaq's minimum bid price listing requirement, aTyr Pharma (NASDAQ:LIFE) will execute a 1:14 reverse split of its common stock after the . . .
Posted on 5/9/19
Boston Scientific To Acquire Vertiflex For $465M
Boston Scientific (NYSE:BSX) has agreed to acquire privately-held Vertiflex, the developer of a device to improve physical function and reduce pain in lumbar spinal stenosis patients
Posted on 5/8/19
J&J To Pay $1B To Settle Bulk Of Litigation Over All-Metal Hips
Bloomberg reports that Johnson & Johnson (JNJ -1.9%) has agreed to pay ~$1B to settle most lawsuits accusing it of selling defective metal-on-metal hips that eventually . . .
Posted on 5/8/19
J&J To Pay $1B To Settle Bulk Of Litigation Over All-Metal Hips
Bloomberg reports that Johnson & Johnson (JNJ -1.9%) has agreed to pay ~$1B to settle most lawsuits accusing it of selling defective metal-on-metal hips that eventually . . .
Posted on 4/22/19
TransMedics Group On Deck For IPO
TransMedics Group (TMDX) has filed a preliminary prospectus for an $86M IPO.The Andover, MA-based medical technology firm has developed a product that it believes is a . . .
Posted on 4/10/19
Rite Aid to Reverse Split Shares 1:20
The board of Rite Aid (NYSE:RAD) has authorized a 1:20 reverse split of its common stock. Post-split trading will commence on April 22.READ FULL ARTICLE HERE
Posted on 3/12/19
J&J's Stelara Shows Positive Action In Late-Stage UC Study
New data from a Phase 3 clinical trial, UNIFI, evaluating Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical's STELARA (ustekinumab) for the maintenance treatment of adults with . . .
Posted on 3/12/19
J&J's Stelara Shows Positive Action In Late-Stage UC Study
New data from a Phase 3 clinical trial, UNIFI, evaluating Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical's STELARA (ustekinumab) for the maintenance treatment of adults with . . .
Posted on 3/8/19
Cronos Closes C$2.4B Altria investment, Names New Execs
Cronos Group (NASDAQ:CRON) has closed the C$2.4B investment from Alria Group (NYSE:MO), representing a 45% ownership stake that would increase to ~55% if Altria exercises its . . .
Posted on 3/6/19
FDA OKs J&J's Esketamine Nasal Spray For Depression
As expected, the FDA approves Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical's SPRAVATO (esketamine) CIII nasal spray, together with an oral antidepressant, for adults with treatment-resistant . . .
Posted on 3/6/19
FDA OKs J&J's Esketamine Nasal Spray For Depression
As expected, the FDA approves Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical's SPRAVATO (esketamine) CIII nasal spray, together with an oral antidepressant, for adults with treatment-resistant . . .
Pittsburgh
